SEC Filing Summary

This filing details transactions made by James Mulay, a director at CG Oncology, Inc., on March 16, 2026. Mulay acquired 654 shares of Common Stock at $3.72 per share and 1310 shares at $12.59 per share. Concurrently, he disposed of 654 shares at $63.50 per share and another 1310 shares at $63.50 per share. These sales were executed under a Rule 10b5-1 trading plan. The filing also reports the acquisition of 654 director stock options with an exercise price of $0 and an underlying value of 654 Common Stock shares, and 1310 stock options with an exercise price of $0 and an underlying value of 1310 Common Stock shares. One option vests starting July 14, 2023, and the other on January 13, 2024.